Background: Mevalonate kinase deficiency (MKD) is a rare genetic autoinflammatory disease caused by blocking of the enzyme mevalonate kinase in the pathway of cholesterol and isoprenoids. The pathogenic mechanism originating an immune response in MKD patients has not been clearly understood.
M
evalonate kinase deficiency (MKD; OMIM no. 251170), is a rare autoinflammatory disease caused by mutations within the second enzyme of the mevalonate pathway (mevalonate kinase (MK), encoded by MVK) (1) . MK is an essential enzyme in isoprenoid biosynthesis; this pathway produces cholesterol and nonsterol intermediate compounds (farnesyl pyrophosphate and geranyl-geranyl pyrophosphate), which are known to be involved in the control of several cell functions through protein prenylation (farnesylation and geranyl-geranylation, respectively) (2) (Figure 1) . The shortage of geranyl-geranyl pyrophosphate, and the consequent decreased rate of protein geranyl-geranylation, leads to increased interleukin (IL)-1β secretion (3) (4) (5) (6) ; this observation gives new insights into MKD pathogenesis, such as the causal link between the cholesterol pathway dysfunction and the patient's phenotype.
Although in the past decade the knowledge of MKD pathogenesis has increased, an etiologic therapy for this orphan drug disease is still unavailable.
Different treatments, including steroids, statins, anti-tumor necrosis factor-α (TNF-α), and anti-IL-1 therapy, have been used with variable success to prevent and cure MKD inflammatory symptoms (7, 8) , whereas only supportive therapies are available for mevalonic aciduria, the more severe form of MKD.
The search for new drugs and therapies for MKD could take advantage of an animal model mimicking the characteristics of the human disease. For this reason, we developed a mouse model of MKD (9) , showing that the chemical inhibition of the mevalonate pathway through the use of an aminobisphosphonate (alendronate (Ald) or pamidronate) and statins (lovastatin) leads to a moderate inflammatory phenotype that could be amplified by bacterial compounds such as muramyl dipeptide (MDP) or lipopolysaccharide (LPS) (10, 11) . Ald inhibits the mevalonate pathway and should regenerate the physiologic activation of a dose-dependent inflammatory process. However, the acute phase of the inflammation is not caused by Ald alone but by Ald together with a proinflammatory agent, i.e., MDP or LPS.
We, and other authors, have recently proposed the use of natural exogenous isoprenoids, such as geraniol (GOH), as a potential therapeutic approach for MKD (10) (11) (12) . Owing to their isoprenoid structure, these compounds are supposed to enter the mevalonate pathway and bypass the biochemical block, thus reconstructing the pathway and limiting the shortage of geranyl-geranyl pyrophosphate (4, 5, 9) . Moreover, the isoprenoids can rescue inflammation in the MKD mouse model (9) as well as in the Ald/lovastatin-LPS-treated Raw 264.7 cell lines (10) , and in human monocytes (13) . Based on the previous partial success of biological drugs, we decided to evaluate the modulation of cytokines and chemokines in our MKD animal model in the presence or in the absence of GOH.
The objective of our study is to compare the inflammation profile of the MKD mouse model with the profile of MKD patients, with the aim of finding analogies useful for the search of new anti-inflammatory drugs and treatments in an established and robust animal model of the disease.
Articles Marcuzzi et al.
RESULTS

Serum Cytokine-Chemokine Levels in MKD Patients
Even if patients showed eight different mutations, expression of IL-1β, IL-5, IL-6, IL-9, and granulocyte colony-stimulating factor (G-CSF) was significantly upregulated, independently of genetic profile, as compared with controls, whereas expression of IL-17, monocyte chemotactic protein-1 (MCP-1), and IL-4 was downregulated in MKD patients as compared with controls ( Table 1 and Figure 2 ).
Serum Cytokine-Chemokine Levels in Ald-Treated Mice
Experimental timing and dosages of Ald were chosen according to the literature: Ald reached the maximum effect 3 d after injection and concentrations <6.5 mg/kg had no effect on the animal, whereas this compound was toxic at concentrations >13 mg/kg (14) .
Serum levels of the cytokines and chemokines IL-1β, IL-5, IL-6, IL-9, IL-17, G-CSF, MCP-1, TNF-α, and IL-4 in control mice and mice treated with different concentrations of Ald are shown in Figure 3 . Blocking the mevalonate pathway resulted in increased values of these cytokine-chemokine levels, with the exception of IL-6, in mice treated with aminobisphosphonate. Moreover, the response to this treatment seemed to be dose-dependent because higher doses of Ald led to higher values of analyzed molecules.
Similarly to MKD patients, IL-4 was downregulated in Aldtreated mice as compared with untreated mice ( Table 2) .
GOH Reduces Inflammatory Cytokine Levels in MKD Mouse Model
We induced an inflammatory state in Ald-treated animals using MDP to mimic the acute phase of the human disease. GOH reduced the MDP-induced inflammatory response in Ald/ MDP-treated mice by entering the pathway and significantly normalizing the expression of the analyzed cytokines and chemokines (Figure 4) . GOH treatment had no significant effect on the tested cytokines if compared with untreated animals (data not shown).
DISCUSSION
In our study we analyzed selected cytokines and chemokines, which are known to increase in human autoinflammatory diseases and are believed to play a role in the pathogenesis of MKD, in patients, controls, and a well-established mouse model (15) . We also analyzed cytokine and chemokine downor upregulation in MKD patients as compared with controls. Our findings are comparable to those observed in our animal model. When considering Ald treatment, the expression levels of IL-1β, IL-5, IL-6, IL-9, IL-17, G-CSF, and MCP-1 were dysregulated as compared with those of controls both in MKD patients and in animals treated with Ald.
TNF-α values in MKD patients did not differ with respect to the controls, whereas they increased in animals treated with Ald. This discrepancy can be explained by the different timing of blood collection. The human samples were collected during a remission period, which can bias the results because TNF-α expression increases during the acute phase and then quickly decreases (half-life of 6 min) (15) . Instead, animal samples were collected under the effect of Ald, which is able to induce a moderate inflammatory response that accounts for the increase of TNF-α expression.
IL-4 is well known to have a strong anti-inflammatory role (16): we observed that a blocked mevalonate pathway downregulates this cytokine in MKD patients and in animals treated with Ald. Moreover, we detected an increase of IL-4 levels in animals after the injection of the proinflammatory molecule MDP (17) and, inversely, a decrease after the administration of GOH, which has anti-inflammatory properties (18, 19) . No theory has been proposed yet to link IL-4 secretion with a dysregulation of the mevalonate pathway. We hypothesize that the observed trend could be linked to the anti-inflammatory role of IL-4. When considering our results, we are aware that the interquartile ranges of cytokine and chemokine expression values in MKD patients are quite wide. This interindividual variability could be explained by hypothesizing the interaction between the MVK genetic defects and the residual MK activity. Indeed, residual MK activity varies from <0.5 to 7%, depending upon the type of MVK mutation (20, 21) . Unfortunately, an evaluation of the quantitative residual MK activity was not available for our patients. Our hypothesis is supported by the fact that, even in mice, the detected amount of cytokines and chemokines seems to be Ald dependent, as different concentrations of Ald led to different responses (22) ; the genetic background could account for these differences.
The consistent variation of cytokine expression in humans and mice suggests that the dysregulation of this particular panel of cytokines could be MKD specific or peculiar to the blocked biosynthesis of cholesterol and/or its intermediates. Indeed, when administered to animals, exogenous GOH was able to bypass the aminobisphosphonate biochemical block, reconstituting the mevalonate pathway and thus normalizing cytokine and chemokine values (23) .
Despite being encouraging, our results need further and deeper investigations aimed at establishing whether GOH could be a potential therapeutic molecule for MKD. We are also aware that the main limits of our study are represented by the different levels of inflammation between the patients with an endogenous block and the mice treated with Ald, and by the fact that the biochemical block of the pathway in the model is substantially different from the genetic defects of patients. To partly overcome these limitations, we are developing a new protocol that extends the times of Ald administration to better mimic the progression of the inflammatory condition of the patient.
In conclusion, even if our findings are preliminary owing to the small number of MKD patients analyzed and the limits related to our animal model, they should be considered as a first step in research aimed at better disclosing the pathogenesis of MKD: the fact that some cytokines and chemokines appear to have a similar dysregulation in MKD patients and in the animal model could be useful for the development of novel therapeutic strategies for this orphan drug disease. The animal 
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Articles model, even with some limitations, was robust enough to be suitable for searching for and testing new drugs for MKD.
METHODS
Reagents
Bacterial MDP and Ald were supplied by Sigma (St Louis, MO). GOH was supplied by Euphar group (Piacenza, Italy).
Blood Samples
After approval by the Independent Bioethics Committee of the IRCCS "Burlo Garofolo" and after written informed consent obtained from parents or caregivers, blood was collected by venipuncture from 35 controls and eight MKD patients; both of the groups were aged between 2 and 9 y ( Table 3) . Controls were individuals without concurrent infections and/or autoimmune diseases. All MKD patients had no concurrent infection and were not in the acute phase of the disease.
Animals
BALB/c male mice (Harlan, Udine, Italy), aged 6-8 wk and weighing between 25 and 30 g were used in this study, which was carried out in accordance with the Italian Ministry of Health registration no. 62/2000-B, 6 October 2000, and approved by the University of Trieste Ethical Committee. The experimental design has been previously described (9) . Briefly, mice were randomly divided into groups of six animals each: group 1, untreated controls; group 2, Ald (6.5 or 13 mg/ kg) on day 0 and MDP 100 μg/kg on day 3; group 3, Ald and MDP as in group 2 plus GOH 250 mg/kg on day 2. All solutions were administered by intraperitoneal route ( Table 4) . After 2 h of MDP stimulation, blood was collected directly into test tubes following decapitation. Serum was obtained by centrifugation at 2,000g at 4 °C and then stored at −80 °C.
Cytokine Release Evaluation
The analysis of 22 cytokines and chemokines (including IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (p40-p70), IL-13, IL-17, eotaxin, G-CSF, granulocyte-macrophage colonystimulating factor, interferon-γ, MCP-1, macrophage inflammatory protein-1α, macrophage inflammatory protein-1β, regulated on activation, normal T cell expressed and secreted, and TNF-α) was performed on serum samples using a magnetic bead-based multiplex immunoassay (Bio-Plex; BIO-RAD Laboratories, Milano, Italy) following the manufacturer's instructions. Data from the reactions were acquired using the Bio-Plex 200 reader, whereas a digital processor managed data output and the Bio-Plex Manager software returned data as median fluorescence intensity and concentration (pg/ml) (BIO-RAD Laboratories). Group 1, untreated controls. Group 2, ald (6.5 or 13 mg/kg) on day 0 and MDP 100 μg/kg on day 3. Group 3, ald and MDP as in group 2 plus GOh 250 mg/kg on day 2. all of the solutions were administered by the intraperitoneal route.
ald, alendronate; GOh, geraniol; MDP, muramyl dipeptide.
